Health Care·Life Sciences Tools & Services·$6.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | +75.00% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.01 | N/A | +75.00% |
| Revenue | N/A | N/A | N/A |
Tone: Neutral
Management acknowledged the current market conditions but emphasized their commitment to strategic initiatives. They did not provide specific guidance for future performance.
Management did not provide specific guidance for the upcoming quarters.
The company is focusing on long-term growth despite current challenges.
Repligen Corp's earnings report showed a small EPS loss, which was better than expected, but the lack of revenue data and guidance may have concerned investors. The stock reacted negatively, dropping 1.46%. Investors will be watching for more clarity on future performance as the company navigates current market conditions.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NISOURCE INC
Feb 1, 2010